These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11515496)

  • 1. A statement of homocyst(e)ine and cardiovascular disease.
    Heart and Stroke Foundation of Canada
    Can J Cardiol; 2001 Jul; 17(7):763-6. PubMed ID: 11515496
    [No Abstract]   [Full Text] [Related]  

  • 2. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease.
    Clarke R; Collins R
    J Cardiovasc Risk; 1998 Aug; 5(4):249-55. PubMed ID: 9919473
    [No Abstract]   [Full Text] [Related]  

  • 3. B vitamins and homocysteine in cardiovascular disease and aging.
    Wilcken DE; Wilcken B
    Ann N Y Acad Sci; 1998 Nov; 854():361-70. PubMed ID: 9928444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocyst(e)inemia--determining factors and treatment.
    Genest J
    Can J Cardiol; 1999 Apr; 15 Suppl B():35B-38B. PubMed ID: 10350684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid, vitamins B6 and B12: relation to homocysteine and cardiovascular disease.
    Kok FJ
    Bibl Nutr Dieta; 2001; (55):189-91. PubMed ID: 11125576
    [No Abstract]   [Full Text] [Related]  

  • 6. Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go?
    Spence JD
    Am J Cardiovasc Drugs; 2001; 1(2):85-9. PubMed ID: 14728038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of homocysteine level lowering therapy and fractures.
    Sawka AM; Ray JG; Yi Q; Josse RG; Lonn E
    Arch Intern Med; 2007 Oct; 167(19):2136-9. PubMed ID: 17954810
    [No Abstract]   [Full Text] [Related]  

  • 8. Homocyst(e)ine, vitamins and genetic interactions in vascular disease.
    Malinow MR
    Can J Cardiol; 1999 Apr; 15 Suppl B():31B-34B. PubMed ID: 10350683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [No scientific evidence supports vitamin B treatment of patients with cardiovascular diseases].
    Ekstedt B; Jansson JH; Boman K
    Lakartidningen; 2006 Nov 8-14; 103(45):3464-6. PubMed ID: 17140177
    [No Abstract]   [Full Text] [Related]  

  • 10. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data.
    Pietrzik K
    Bibl Nutr Dieta; 2001; (55):34-41. PubMed ID: 11125582
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
    Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
    G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical and economic effects of homocyst(e)ine lowering.
    Nallamothu BK; Fendrick AM; Rubenfire M; Saint S; Bandekar RR; Omenn GS
    Arch Intern Med; 2000 Dec 11-25; 160(22):3406-12. PubMed ID: 11112233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamins and minerals 4: overview of folate and the B vitamins.
    Thompson J
    Community Pract; 2006 Jun; 79(6):197-8. PubMed ID: 16780289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension?
    Virdis A; Ghiadoni L; Salvetti G; Versari D; Taddei S; Salvett A
    J Nephrol; 2002; 15(4):414-21. PubMed ID: 12243373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia.
    Peterson JC; Spence JD
    Lancet; 1998 Jan; 351(9098):263. PubMed ID: 9457098
    [No Abstract]   [Full Text] [Related]  

  • 17. [Group B vitamins as new variables related to the cardiovascular risk].
    Granieri M; Bellisarii FI; De Caterina R
    Ital Heart J Suppl; 2005 Jan; 6(1):1-16. PubMed ID: 15776726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhomocysteinemia as a cause of vascular occlusion in end-stage-renal disease.
    Tamura T; Bergman SM; Morgan SL
    Int J Artif Organs; 1998 Feb; 21(2):72-4. PubMed ID: 9569127
    [No Abstract]   [Full Text] [Related]  

  • 19. Homocysteine or renal impairment: which is the real cardiovascular risk factor?
    Potter K; Hankey GJ; Green DJ; Eikelboom JW; Arnolda LF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1158-64. PubMed ID: 18356552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.